Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

09 July 2021: Clinical Research

Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of <5 g/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China

Chunmei Ye 12BCEF* , Weiwei Chen 3EF* , Qi Gao 12B , Yanxia Chen 4B , Xiaolu Song 5B , Sujie Zheng 2C* , Jinlin Liu 2AEG*

DOI: 10.12659/MSM.930241

Med Sci Monit 2021; 27:e930241

Supplementary Table 1 Details of the clinical characteristics of 45 multiple myeloma patients.

CaseSexAge (years)Live statusDate of deathSurvival time (month)SubtypeLocalization of infectionInfection timeInfectious episodesProphylactic antibioticsOther treatmentTreatment options
1F79Died2019-0886IgA, λUpper respiratory tract20121+__PD/MP
2F74Died2019-0153IgA, λLung20141____Velcade + MP
4F53Died2016-0636IgA, κUpper respiratory tract2013/20163/2+__VAD/PD+Pirarubicin
5M52Died2015-0727IgD, λLung,skin2013/2014/20152/4/4+__VAD/CTD/CVAD
6M47Died2014-0226IgG, λLung2012/20161/1____PD/VBAP
7M72Died2018-0924UnclearLung, gingiva, skin2016/2017/20181/2/3____PD/PCD
8M52Died2014-0322IgA, λLung, urinary tract, bronchi2012/2013/20144/1/1+HSCTVASD/PD/ PCD
9M49Died2015-0319IgA, λCrissum, upper respiratory tract2013/20143/2____VAD/MPT
10M62Died2018-0116IgA, λLung2016/20171/2____Cyclophosphamide+GC
11F34Died2017-1211λLung, gingiva, bladder20175__CAR-T/HSCTPAD/DTPACE+Velcade
12M73Died2019-0211IgA, λLung2017/20181/1____VAD/MPTC
13M78Died2013-0110IgA, κUpper respiratory tract20122____VAD
14M67Died2019-0810IgD, λLung20191____DT
15M84Died2019-026IgA, λSkin20182+__PD
16M86Died2016-106IgD, λFever20161______
17M62Died2013-065IgD, λFever20131____VAD/MP+ Velcade
19M58Died2016-034IgA, λLung20151____VAD
21M71Died2012-123IgA, κ__________MP/VAD/DT
23M77Died2014-061IgA, κLung2011/2012/20141/1/1____DL
24F67Died2017-071IgA, κUpper respiratory tract2015/2016/20171/2/1+__PCD
25M83Died2017-101IgA, λLung20172__PD
26M45Died2020-0613IgA, κFever20201+CAR-TDECP/TCD/IRD
27M70Survival__59IgA, λLung20201+__PCD/RD
29M65Survival__12κSkin, esophagus2019/20201/1____PD
30M84Survival__15IgA, κLung20191____PD
31M67Survival__17IgA, λ__________PCD/IRD
32M77Survival__12IgA, λLung20191____PD
34M79Survival__21IgA, λ______+__DI
35F50Survival__21λLung, urinary tract20193+CAR-TPCD/DECP/FC
36F52Survival__20IgA, κLung, urinary tract, Skin20195+HSCTPD/PDT
37M76Survival__30IgA, κLung, skin2019/20203/1+CAR-TFC/DECP
38F58Survival__22IgD, λLung, upper respiratory tract2018/20191/1__IVIGPAD
39F70Survival__38IgA, λLung20171____PD
40M48Survival__20IgA, κLung, upper respiratory tract2018/20193/1__IVIGPAD/PADT
41M54Survival__32κLung20191____PCD/PAD/ DTPACE
42M27Survival__37κLung, upper respiratory tract2017/20182/2+IVIG/ HSCTPAD/DTPACE+ Velcade
43F66Survival__14IgA, κLung20191____DECP/FC/PCD
44M58Survival__69IgA, κLung2014/20151/1____VADT
45M40Survival__20IgA, λLung20191____PCD
No infection episode was documented in cases18, 21, 31, and 34 during one-time hospitalization in Zhejiang Provincial People’s Hospital. Infection time available in Zhejiang Provincial People’s Hospital is fully listed in . F – Female; M – Male; + – Yes; __ – No. HSCT – hematopoietic stem cell transplant; GC – glucocorticoid; CAR-T – chimericantigenreceptor T cell; IVIG – intravenous immunoglobulin; VAD – vincristine + adriamycin + dexamethasone; VADT – vincristine + adriamycin + dexamethasone + thalidomide; DECP – dexamethasone + etoposide + cyclophosphamide + cisplatin; DTPACE – dexamethasone + thalidomide + cisplatin + adriamycin + cyclophosphamide + etoposide; PAD – bortezomib + epirubicin + dexamethasone; PAD – bortezomib + adriamycin + dexamethasone; MP – melphalan + prednisone; DT – dexamethasone + thalidomide; DL – dexamethasone + lenalidomide; PD – bortezomib + dexamethasone; PCD – bortezomib + cyclophosphamide + dexamethasone; VBAP – vinblastine + bleomycin + adriamycin + prednisone; PADT – bortezomib + adriamycin + dexamethasone + thalidomide; TPACE – thalidomide + cisplatin + adriamycin + cyclophosphamide + etoposide; FC – fludarabine + cyclophosphamide; CVAD – cyclophosphamide + vincristine + adriamycin + dexamethasone; CDT – cyclophosphamide + dexamethasone + thalidomide; MPTC – melphalan + prednisone + thalidomide + cyclophosphamide; MPT – melphalan + prednisone+thalidomide; TCD – thalidomide+cyclophosphamide+dexamethasone; IRD – ixazomib+lenalidomide+dexamethasone; RD – lenalidomide+dexamethasone; DI – dexamethasone+ixazomib; PDT – bortezomib+dexamethasone+thalidomide.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750